Date post: | 20-Aug-2015 |
Category: |
Health & Medicine |
Upload: | learfieldinteraction |
View: | 1,004 times |
Download: | 0 times |
Clinical Guidelines—Pneumococcal Vaccination in Older Adults for the Prevention of Pneumococcal Disease
2
Background
Pneumococcal disease is
• an invasive disease from Streptococcus pneumoniae (pneumococcus),
• the leading cause of vaccine-preventable illness and death in the U.S., and
• more dangerous to young children and the elderly (≥65).
3
Transmission
Pneumococcus is
•found in many people’s noses and throats as a type of bacteria, and
•spread by coughing, sneezing or via contact with respiratory secretions.
6
Those at Greatest RiskUnderlying Conditions
Long-Term Health Problems
Weakened Immune System
Heart or lung disease, sickle cell, diabetes, alcoholism, cirrhosis, leaks of cerebrospinal fluid, cochlear implant
Hodgkin’s lymphoma, leukemia, kidney failure, multiple myeloma, nephrotic syndrome, HIV or AIDS, damaged or no spleen, organ transplant
8
Clinical Syndromes
lungs (pneumonia)
blood (bacteremia)
covering of the brain(meningitis)
Pneumoccocus leads to serious infections of the
9
Clinical SyndromesMortality Rates
Pneumonia
1 in 20
deaths
Bacteremia
1 in 5
deaths
Meningitis
3 in 10
deaths
10
Clinical SyndromesMortality Rates
The highest mortality for bacteremia and meningitis occurs among the elderly and patients with underlying conditions.
11
Pneumonia
• Most common disease caused by pneumococcal infection
• 175,000 estimated U.S. cases annually
• Occurs alone or in combination with bacteremia and/or meningitis
• Not considered invasive but can be severe when isolated
12
Pneumonia
• 1–3 day incubation period
• 5–7% fatality rate (may be much higher among elderly)
• Accounts for 36% of adult community-acquired pneumonia; 50% of hospital-acquired pneumonia
14
Bacteremia
Approximately 1 in 4 patientswith pneumonia develop bacteremia
More than 5,000 U.S. cases annually
20% overall case fatality
May be as high as 60%among elderly
16
Meningitis
Accounts for 13–19% of all pneumococcal disease cases in the U.S.
Highest rate in children <1 year old
As high as 80% elderly mortality rate
18
Vaccination
Approximately half of deaths from pneumococcal disease could be prevented by vaccinations.
50%
19
PPSV23 Vaccine
Pneumococcal disease has more than 90 serotypes.
The 10 most common serotypes cause 62% of invasive disease worldwide.
PPSV23 protects against 23 serotypes, including those most likely to cause serious disease.
20
PPSV23 VaccineEfficacy
PPSV23 IS
•60–70% effective against invasive disease,
•very good at preventing severe disease, hospitalization and death, and
•effective at developing antibodies within 2–3 weeks in more than 80% of healthy adults.
21
PPSV23 VaccineEfficacy
PPSV23 IS NOT
•a “pneumonia vaccine,”
•shown to provide protection against pneumococcal pneumonia, and
•guaranteed to prevent infection and symptoms in all people.
22
PPSV23 VaccineRecommendations
Adults 65 years and older
Anyone 2–64 years old with a long-term health problem,heart disease, lung disease, sickle cell disease, diabetes, alcoholism, cirrhosis, leaks of the cerebrospinal fluid or cochlear implant
Updated recommendations for prevention of invasive pneumoccocal diseaseamong adults using the PPSV23 vaccine.Source: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm
23
PPSV23 Vaccine Recommendations
Anyone 2–64 years old with a disease or condition thatlowers the body’s resistance to infectionHodgkin’s lymphoma, leukemia, kidney failure, multiple myeloma, nephrotic syndrome, HIV infection or AIDS, damaged or no spleen, organ transplant
Anyone 2–64 years old taking a drug or treatment thatlowers the body’s resistance to infectionlong-term steroids, certain cancer drugs, radiation therapy
Any adult 19–64 years old who is a smoker or hasasthma
24
PPSV23 Vaccine Recommendations
Older adults and persons with chronic illnesses or immunodeficiency may not respond well, if at all;
however,
it is still recommended because they are at high risk of developing severe disease.
26
PPSV23 VaccineDosing Exceptions
Revaccination is recommended for•People ≥65 years who got first dose younger than 65 and more than 5 years have passed•People 2–64 years given first dose >5 years ago who have
o a damaged or no spleeno sickle-cell diseaseo HIV infection or AIDSo cancer, leukemia,
lymphoma, multiple myeloma
o nephrotic syndromeo an organ or bone marrow
transplanto to take medication that lowers
immunity (chemotherapy, long-term steroids)
27
PPSV23 VaccineExclusions
Anyone
•with a life-threatening allergic reaction to PPSV23
•with a severe allergy to any component of the vaccine*
•moderately to severely ill at time of administration
•pregnant** or potentially pregnant
* See CDC Pink Book in Resources at the end of this presentation for vaccine components.** No evidence exists that PPSV23 would be harmful to a pregnant woman or her fetus.
28
PPSV23 VaccineRisks
• Mild side effects (redness or pain at the injection site)
• Fever, muscle aches, or more severe local reactions in <1%
• Rare serious reaction, as with all vaccines
29
PPSV23 VaccineRisks
PPSV23 cannot possibly cause pneumococcal disease.
It is an inactivated vaccine that contains only a portion of the microbe.
30
PPSV23 Vaccine Medicare Coverage
Coverage includes
•Vaccine and its administration by recognized providers
•Booster vaccine for high-risk patients, if >5 years since original vaccine
•No coinsurance, copayment, or deductible requirements for patient
More detail? Centers for Medicare & Medicaid Services (CMS)
2011-2012 Immunizers’ Question & Answer Guide
31
PPSV23 VaccineEndorsements
The Centers for Disease Control and Prevention
The Advisory Committee on Immunization Practices
The American Academy of Pediatrics
The American College of Obstetricians and Gynecologist
s
The American Academy of Family Physicians
The American College of Physicians
32
PPSV23 VaccinePocket Guide
A laminated quick-reference tool from the CDC for front-line healthcare personnel is available.
Order here: http://www.immunize.org/ppvguide/
34
Resources
From the CDC:
• Clinical Information on Pneumococcal
• Updated Recommendations for the Prevention of Invasive Pneumoccal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)
• Pneumococcal Disease In-Short
• PPSV23 What You Need to Know
• Standing Orders for Administering Pneumococcal Vaccine to Adults
• Pneumoccoccal Disease, Chapter 16 from the CDC Pink Book
From the Immunization Action Coalition:
• Ask the Experts
• Vaccine Information